Syros Total Stockholder Equity from 2010 to 2024
| SYRS Stock | USD 0.28 0.08 22.22% |
Total Stockholder Equity | First Reported 2014-12-31 | Previous Quarter -6.4 M | Current Value -11.1 M | Quarterly Volatility 36.6 M |
Check Syros Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Syros Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 5.4 M or Selling General Administrative of 18.9 M, as well as many indicators such as Price To Sales Ratio of 21.1, Dividend Yield of 0.0 or PTB Ratio of 13.91. Syros financial statements analysis is a perfect complement when working with Syros Pharmaceuticals Valuation or Volatility modules.
Syros | Total Stockholder Equity |
Latest Syros Pharmaceuticals' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Syros Pharmaceuticals over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Syros Pharmaceuticals' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Syros Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Syros Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 64,996,527 | |
| Geometric Mean | 57,208,354 | |
| Coefficient Of Variation | 44.00 | |
| Mean Deviation | 20,296,975 | |
| Median | 60,241,000 | |
| Standard Deviation | 28,601,181 | |
| Sample Variance | 818T | |
| Range | 111.9M | |
| R-Value | 0.02 | |
| Mean Square Error | 880.4T | |
| R-Squared | 0.0006 | |
| Significance | 0.93 | |
| Slope | 157,908 | |
| Total Sum of Squares | 11452.4T |
Syros Total Stockholder Equity History
About Syros Pharmaceuticals Financial Statements
Syros Pharmaceuticals shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Syros Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Syros Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Syros Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 16.7 M | 15.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.